- Conditions
- Pneumococcal Disease
- Interventions
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 42 Days to 98 Days
- Enrollment
- 1,997 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 105
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 78 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 60
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pneumococcal Infection
- Interventions
- V116, PCV20
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,663 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 52 more
- Conditions
- Pneumococcal Disease
- Interventions
- 20vPnC, 13vPnC, PPSV23, Saline
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,902 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 45 more
- Conditions
- Pneumococcal Immunization
- Interventions
- PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, RotaTeq, Vaxelis vaccine, Varivax, Hexaxim Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 1,714 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 66
- States / cities
- Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 48 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more
- Conditions
- Pneumococcal Disease
- Interventions
- PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 4,670 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Lake Forest, California • Walnut Creek, California + 28 more
- Conditions
- Pneumococcal Vaccines
- Interventions
- 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 802 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 32
- States / cities
- Jonesboro, Arkansas • Madera, California • Tampa, Florida + 22 more
- Conditions
- Pneumococcal Infections
- Interventions
- V114, Prevnar 13™, PNEUMOVAX™23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Orlando, Florida • West Palm Beach, Florida • Houston, Texas
- Conditions
- Pneumococcal Disease
- Interventions
- V116, PPSV23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 2,162 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 30
- States / cities
- Mesa, Arizona • Tempe, Arizona • Little Rock, Arkansas + 27 more
- Conditions
- Asthma
- Interventions
- Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)
- Biological
- Lead sponsor
- Rohit Divekar
- Other
- Eligibility
- 19 Years to 20 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pneumococcal Vaccines
- Interventions
- 24-Valent Pneumococcal Conjugate Vaccine, Pneumococcal 20-valent Conjugate Vaccine
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • DeLand, Florida • Hollywood, Florida + 17 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab, methotrexate, 23-Valent Pneumococcal Polysaccharide Vaccine, Tetanus Toxoid Adsorbed Vaccine
- Biological · Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 47
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 42 more
- Conditions
- Pneumococcal Infections
- Interventions
- V114, Prevnar 13™, PNEUMOVAX™23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 13
- States / cities
- Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 10 more
- Conditions
- Pneumococcal Infection
- Interventions
- V116, PPSV23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Madera, California + 23 more
- Conditions
- Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
- Interventions
- AFX3772, Prevnar 13, Prevnar 20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 42 Days to 90 Days
- Enrollment
- 388 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 42
- States / cities
- Jonesboro, Arkansas • Los Angeles, California • Miami, Florida + 35 more
- Conditions
- Pneumococcal Disease
- Interventions
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 225 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 35
- States / cities
- Washington D.C., District of Columbia • Miami, Florida • Chamblee, Georgia + 18 more
- Conditions
- Streptococcus Pneumoniae
- Interventions
- PG4 vaccine in Buffer 1 with low dose PA-001, PG4 in Buffer 1 with low dose PA-002, PG4 in Buffer 1 with high dose PA-001, PG4 vaccine in Buffer 1 with high dose PA-002, PG4 vaccine in Buffer 2, 20-valent pneumococcal conjugate vaccine, Saline injection
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years to 84 Years
- Enrollment
- 380 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Lake Forest, California • Rolling Hills Estates, California • Greenacres City, Florida + 13 more
- Conditions
- Pneumococcal Vaccines
- Interventions
- 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 45
- States / cities
- Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 32 more
- Conditions
- Pneumococcal Vaccines
- Interventions
- 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,015 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 25
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Hollywood, Florida + 22 more
- Conditions
- Pneumococcal Disease
- Interventions
- 20vPnC
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 15 Months to 17 Years
- Enrollment
- 839 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 43
- States / cities
- Fayetteville, Arkansas • Jonesboro, Arkansas • San Diego, California + 30 more
- Conditions
- Pneumococcal Infections
- Interventions
- V114, Prevnar 13™, PNEUMOVAX™23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 652 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 15
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Spring Valley, California + 12 more
- Conditions
- Pneumococcal Vaccines
- Interventions
- 31-valent pneumococcal conjugate vaccine, PCV20
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 752 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 30
- States / cities
- Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more
- Conditions
- Pneumonia, Pneumococcal
- Interventions
- V116, Pneumovax™23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Coral Gables, Florida + 15 more
- Conditions
- Pneumococcal Immunization
- Interventions
- PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 580 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Hollywood, Florida • Miami, Florida + 13 more